Embryonic stem cell

ModalAI Expands Suite of NDAA-Compliant Drone Components to Advance U.S. Drone Industry

Retrieved on: 
Tuesday, March 19, 2024
Software, Networks, Hardware, Robotics, Electronic Design Automation, Technology, Drones, Automotive, Autonomous Driving, Vehicles, Artificial Intelligence, 5G, Other Technology, Telecommunications, FPV, Embryonic stem cell, DIU, Blue, SLAM, 40A, Onsemi, Perception, SWAP, AI, UAS, Unmanned aerial vehicle, PCB, NDAA, Multimedia, Movement, Printed circuit board

ModalAI , a Blue UAS Framework drone and autopilot manufacturer, celebrated for its 16g autonomous UAS autopilot VOXL 2 , today announced availability of NDAA-compliant drone accessories.

Key Points: 
  • ModalAI , a Blue UAS Framework drone and autopilot manufacturer, celebrated for its 16g autonomous UAS autopilot VOXL 2 , today announced availability of NDAA-compliant drone accessories.
  • ModalAI is expanding its technology offerings with the addition of three ESCs and a computer vision image sensor.
  • (Photo: Business Wire)
    ModalAI has been at the forefront of manufacturing UAS components that are compliant with the NDAA ‘20 Section 848.
  • “VOXL 2 is driving the industry to advanced, state of the art UAS,” said Chad Sweet, CEO and co-founder of ModalAI.

Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets

Retrieved on: 
Tuesday, December 12, 2023
Microsoft Exchange Server, DSM-IV codes, Research, Prevalence, Takeda Pharmaceutical Company, IND, RTI Surgical, Investment, NuVasive, Market development, Patient, ALS, PVT, COVID-19, Stem cell, Master of ceremonies, US FDA, Technical, Cancer, Pulse, RESEARCH, Growth, Embryonic stem cell, Ethics, Adipose tissue, Silk, Veterinary medicine, Pharmaceutical industry

The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.

Key Points: 
  • The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.
  • Stem Cell Therapy Market Dynamics:
    Key Market Players of Stem Cell Therapy Industry:
    The stem cell therapy market is competitive, with a small number of players competing for market shares.
  • Stem Cell Therapy Market - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments.
  • The report provides insights on the following pointers:
    Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.

Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets

Retrieved on: 
Tuesday, December 12, 2023
Microsoft Exchange Server, DSM-IV codes, Research, Prevalence, Takeda Pharmaceutical Company, IND, RTI Surgical, Investment, NuVasive, Market development, Patient, ALS, PVT, COVID-19, Stem cell, Master of ceremonies, US FDA, Technical, Cancer, Pulse, RESEARCH, Growth, Embryonic stem cell, Ethics, Adipose tissue, Silk, Veterinary medicine, Pharmaceutical industry

The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.

Key Points: 
  • The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.
  • Stem Cell Therapy Market Dynamics:
    Key Market Players of Stem Cell Therapy Industry:
    The stem cell therapy market is competitive, with a small number of players competing for market shares.
  • Stem Cell Therapy Market - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments.
  • The report provides insights on the following pointers:
    Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.

Global Rat Model Market to Reach $2.41 Billion by 2030 with a CAGR of 7.06%: Key Insights and Growth Factors Unveiled

Retrieved on: 
Tuesday, October 31, 2023
Rat, Gene editing, Human, Incidence, Molecular biology, Therapy, Vaccine, Dihydrolipoyllysine-residue (2-methylpropanoyl)transferase, Toxicology, CRISPR, Prevalence, Embryonic stem cell, Human Genome Project, Phenotype, Research, Application, Microinjection, Growth, Disease, COVID-19, Breeding, Outcrossing, Envigo, USD, ZFN, GEM, Agriculture, Medical device

The global rat model market size is expected to reach USD 2.41 billion by 2030., expanding at a CAGR of 7.06% from 2023 to 2030.

Key Points: 
  • The global rat model market size is expected to reach USD 2.41 billion by 2030., expanding at a CAGR of 7.06% from 2023 to 2030.
  • Genetically modified organisms are extensively used in research for identifying potential therapeutic targets and further validation of the same.
  • The extensive healthcare-based research has driven the market for understanding diseases and genetic illnesses of humans.
  • Increased spending on research and growing number of clinical trials are the key factors contributing to the market growth.

clock.bio Launches to Decode Rejuvenation Biology Across the Human Genome

Retrieved on: 
Thursday, August 31, 2023
Science, Stem Cells, Biotechnology, Research, Health, Cosmetics, Clinical Trials, Retail, Embryonic stem cell, CRISPR, Rejuvenation, IPSC, EIR, Ageing, Quality of life, Biomarker, Cell, McKinsey & Company, Meatable, Cell potency, Biology, Longevity, Notifiable disease, Gene, Economics, Genome, Disease, Pharmaceutical industry, Veterinary medicine, Vaccine

The company’s immediate scientific objective is to decode all rejuvenation programs present in human cells, to build an atlas of disease and rejuvenation targets for clinical translation.

Key Points: 
  • The company’s immediate scientific objective is to decode all rejuvenation programs present in human cells, to build an atlas of disease and rejuvenation targets for clinical translation.
  • Embryonic stem cells hold the key to unlocking rejuvenation biology,” said Mark Kotter, Founder, clock.bio.
  • clock.bio is on track to decode the biology of human rejuvenation across the entire genome in 12 months.
  • Its vision is to use this technology to enable a comprehensive decoding of rejuvenation biology, to create novel treatment approaches.

Linewize Selected as Preferred Technology Provider for Texas Schools in a Strategic Partnership with the Technology Alliance for Statewide Initiatives (TASI)

Retrieved on: 
Tuesday, August 8, 2023
Embryonic stem cell, Partnership, TASI, Tutoring

CHARLOTTE, N.C., Aug. 8, 2023 /PRNewswire/ -- Linewize, a division of global safety and student wellbeing leader Qoria, is proud to announce a preferred vendor partnership with Texas' Technology Alliance for Statewide Initiatives (TASI).

Key Points: 
  • Through this partnership, Texas' ESCs and school districts will have access to premium tools with transparent pricing and the support they need to cater to the challenges of today's schooling.
  • "We are grateful to have been chosen, through a competitive process, as a preferred vendor for the Texas school systems.
  • We're truly excited by the opportunity to partner with TASI to support innovation and student wellbeing in Texas," said Stephen Mirante, vice president of strategic relations at Linewize.
  • "By working closely with the TASI team and their district membership, we seek to honor our mission to protect and support every child's digital journey."

Global Stem Cell Research Leader, CHA Medical & Bio Group Expands Its Global Presence With Launch of Anti-Aging Research Institute in Los Angeles, Ca.

Retrieved on: 
Thursday, May 25, 2023
Health, Stem Cells, Genetics, Research, Science, Pharmaceutical, Biotechnology, GMP, CHA, Embryonic stem cell, Rejuvenation, HLA, Oregon Health & Science University, Gene editing, Clinical trial, Cha University, Multimedia, History, Cerebral palsy, Food and Drug Administration, Regeneration, CDMO, Patent, OHSU, Stem cell, School of Life Sciences (University of Dundee), Epithelium, SCNT, International Student Congress Of (bio)Medical Sciences, Food, Vaccine

CHA Medical & Bio Group, a global leader in stem cell research based in South Korea, announced its plan to establish the CHA Power Aging Research Translational Institute (CHA PARTI) in Los Angeles.

Key Points: 
  • CHA Medical & Bio Group, a global leader in stem cell research based in South Korea, announced its plan to establish the CHA Power Aging Research Translational Institute (CHA PARTI) in Los Angeles.
  • In 2014, CHA Medical & Bio Group established the first-ever cloned stem cell lines using adult somatic stem cells.
  • (Graphic: Business Wire)
    CHA PARTI, a collaborative research institute involving CHA Biotech, CHA University, and CHA Medical & Bio Group is scheduled to open later this year.
  • CHA Medical & Bio Group has been at the forefront of stem cell research and gained global recognition for these innovative efforts.

Stem Cell/Cord Blood Banking Global Market Report 2023: Sector to Reach $16.36 Billion by 2027 at a 10.1% CAGR - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 21, 2023
Health, Stem Cells, Benchmark, Stem cell, Natera, B cell, Diabetes, Create, Agriculture, Small business, Coronavirus, News, Cancer, The Cooper Companies, Pregnancy, Birth control, Collection, Spectrum, Cell, Public law, Cerebral palsy, Obstetrics, Multiple myeloma, Transplant, Embryonic stem cell, Acquisition, FDA, Patient, Anemia, Regenerative medicine, Canadian International Council, Thalassemia, Haematopoietic system, Leukemia, US Foods, AABB, Blood, William Cooper (co-operator), Parent, Genetic testing, WebMD, Food, Vaccine, Pharmaceutical industry, Gynaecology

The main cell types of stem cell/cord blood banking are adult stem cells, umbilical cord blood stem cells, and embryonic stem cells.

Key Points: 
  • The main cell types of stem cell/cord blood banking are adult stem cells, umbilical cord blood stem cells, and embryonic stem cells.
  • Increasing number of cancer patients is a major driver for the stem cell /cord blood banking market.
  • Pairing of cord blood and tissue storage with genetic testing services is an emerging trend in the stem cell/cord blood banking market.
  • 1) By Cell Type: Adult Stem Cells; Umbilical Cord Blood Stem Cells; Embryonic Stem Cells

Induced Pluripotent Stem Cells Production Global Market Report 2022: Sector to Reach $2.8 Billion by 2030 at a 9.2% CAGR

Retrieved on: 
Monday, January 9, 2023
Severe acute respiratory syndrome coronavirus 2, Blastomere, Degenerative disease, Cell culture, Stroke, Regenerative medicine, SARS, International Diabetes Federation, Heart, Biotechnology, Drug discovery, Therapy, Potency (pharmacology), IDF, Research, Drug development, Destiny, ESC, COVID-19, USD, Growth, Patient, Embryonic stem cell, B cell, Process, Conditional sentence, Business analysis, Chapter Five, Diabetes, Marketspace, Prevalence, Cell, Renewable energy, Pharmaceutical industry, Fine chemical, Workflow

The global induced pluripotent stem cells production market size is estimated to reach USD 2.8 billion by 2030.

Key Points: 
  • The global induced pluripotent stem cells production market size is estimated to reach USD 2.8 billion by 2030.
  • The increase in demand for induced pluripotent stem cells (iPSCs) in comparison to Embryonic Stem Cells (ESCs) has offered a significant drive to the market.
  • Induced pluripotent stem cells are cells that are derived from adult somatic cells and then further reprogrammed to obtain the pluripotency as that of ESCs.
  • The key factors driving the revenue growth are the developed healthcare infrastructure, the prevalence of chronic diseases, the presence of strategic business models and funds by supportive government
    Chapter 4 Induced Pluripotent Stem Cells (Ipscs) Production Market: Process Business Analysis
    Chapter 5 Induced Pluripotent Stem Cells (Ipscs) Production Market: Workflow Business Analysis
    Chapter 6 Induced Pluripotent Stem Cells (Ipscs) Production Market: Product Business Analysis
    Chapter 7 Induced Pluripotent Stem Cells (Ipscs) Production Market: Application Business Analysis
    Chapter 8 Induced Pluripotent Stem Cells (Ipscs) Production Market: End-User Business Analysis
    Chapter 9 Induced Pluripotent Stem Cells (Ipscs) Production Market: Regional Business Analysis

Induced Pluripotent Stem Cells Production Global Market Report 2022: Absence of Ethical Issues, Personalized Treatment Options and Flexibility Drive Adoption - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Health, Stem Cells, Severe acute respiratory syndrome coronavirus 2, Blastomere, Degenerative disease, Cell culture, Stroke, Regenerative medicine, SARS, International Diabetes Federation, Heart, Biotechnology, Drug discovery, Therapy, Potency (pharmacology), IDF, Research, Drug development, Destiny, ESC, COVID-19, USD, Growth, Patient, Embryonic stem cell, B cell, Process, Conditional sentence, Business analysis, Chapter Five, Diabetes, Marketspace, Prevalence, Cell, Renewable energy, Pharmaceutical industry, Fine chemical, Workflow

The global induced pluripotent stem cells production market size is estimated to reach USD 2.8 billion by 2030.

Key Points: 
  • The global induced pluripotent stem cells production market size is estimated to reach USD 2.8 billion by 2030.
  • The increase in demand for induced pluripotent stem cells (iPSCs) in comparison to Embryonic Stem Cells (ESCs) has offered a significant drive to the market.
  • Advantages such as no stem cell-related ethical issues, personalized treatment, and flexibility during cell-based research have created a favorable scenario for market growth.
  • The key factors driving the revenue growth are the developed healthcare infrastructure, the prevalence of chronic diseases, the presence of strategic business models and funds by supportive government
    Chapter 4 Induced Pluripotent Stem Cells (Ipscs) Production Market: Process Business Analysis
    Chapter 5 Induced Pluripotent Stem Cells (Ipscs) Production Market: Workflow Business Analysis
    Chapter 6 Induced Pluripotent Stem Cells (Ipscs) Production Market: Product Business Analysis
    Chapter 7 Induced Pluripotent Stem Cells (Ipscs) Production Market: Application Business Analysis
    Chapter 8 Induced Pluripotent Stem Cells (Ipscs) Production Market: End-User Business Analysis
    Chapter 9 Induced Pluripotent Stem Cells (Ipscs) Production Market: Regional Business Analysis